These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 21757465)

  • 41. Atorvastatin affects several angiogenic mediators in human endothelial cells.
    Dulak J; Loboda A; Jazwa A; Zagorska A; Dörler J; Alber H; Dichtl W; Weidinger F; Frick M; Jozkowicz A
    Endothelium; 2005; 12(5-6):233-41. PubMed ID: 16410222
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative expression profiling in primary and immortalized endothelial cells: changes in gene expression in response to hydroxy methylglutaryl-coenzyme A reductase inhibition.
    Boerma M; Burton GR; Wang J; Fink LM; McGehee RE; Hauer-Jensen M
    Blood Coagul Fibrinolysis; 2006 Apr; 17(3):173-80. PubMed ID: 16575254
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells.
    Mausner-Fainberg K; Luboshits G; Mor A; Maysel-Auslender S; Rubinstein A; Keren G; George J
    Atherosclerosis; 2008 Apr; 197(2):829-39. PubMed ID: 17826781
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Atorvastatin increases expression of low-density lipoprotein receptor mRNA in human circulating mononuclear cells.
    Pocathikorn A; Taylor RR; Mamotte CD
    Clin Exp Pharmacol Physiol; 2010 Apr; 37(4):471-6. PubMed ID: 19930424
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor Atorvastatin mediated effects depend on the activation status of target cells in PLP-EAE.
    Mix E; Ibrahim SM; Pahnke J; Glass A; Mazón-Peláez I; Lemcke S; Koczan D; Gimsa U; Bansemer S; Scheel T; Karopka T; Böttcher T; Müller J; Dazert E; Antipova V; Hoffrogge R; Wree A; Zschiesche M; Strauss U; Kundt G; Warzok R; Gierl L; Rolfs A
    J Autoimmun; 2006 Dec; 27(4):251-65. PubMed ID: 17085013
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor.
    Stern RH; Yang BB; Hounslow NJ; MacMahon M; Abel RB; Olson SC
    J Clin Pharmacol; 2000 Jun; 40(6):616-23. PubMed ID: 10868312
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mitohormesis: another pleiotropic effect of statins?
    Liao JK
    Eur Heart J; 2012 Jun; 33(11):1299-301. PubMed ID: 21979988
    [No Abstract]   [Full Text] [Related]  

  • 48. RNA-sequencing analysis of HepG2 cells treated with atorvastatin.
    Stormo C; Kringen MK; Lyle R; Olstad OK; Sachse D; Berg JP; Piehler AP
    PLoS One; 2014; 9(8):e105836. PubMed ID: 25153832
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo.
    Klein K; Thomas M; Winter S; Nussler AK; Niemi M; Schwab M; Zanger UM
    Clin Pharmacol Ther; 2012 Jun; 91(6):1044-52. PubMed ID: 22510778
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bioenergetic study of murine hepatic tissue treated in vitro with atorvastatin.
    Alfazari AS; Al-Dabbagh B; Almarzooqi S; Albawardi A; Souid AK
    BMC Pharmacol Toxicol; 2013 Feb; 14():15. PubMed ID: 23448291
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Regulation of leukemic cell differentiation and retinoid-induced gene expression by statins.
    Sassano A; Lo Iacono M; Antico G; Jordan A; Uddin S; Calogero RA; Platanias LC
    Mol Cancer Ther; 2009 Mar; 8(3):615-25. PubMed ID: 19240159
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Statin Treatment Induced a Lipogenic Expression Hierarchical Network Centered by SREBF2 in the Liver.
    Song S; Niu M; Liang Q; Wang L; Min H; Peng Y; Wang H; Gao Q
    Front Endocrinol (Lausanne); 2021; 12():573824. PubMed ID: 34349727
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetic interactions of statins.
    Reinoso RF; Sánchez NA; García MJ; Prous JR
    Methods Find Exp Clin Pharmacol; 2001 Dec; 23(10):541-66. PubMed ID: 11957745
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A framework for identification of on- and off-target transcriptional responses to drug treatment.
    Huang Y; Furuno M; Arakawa T; Takizawa S; de Hoon M; Suzuki H; Arner E
    Sci Rep; 2019 Nov; 9(1):17603. PubMed ID: 31772269
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Topoisomerase I inhibition leads to length-dependent gene expression changes in human primary astrocytes.
    Gokoolparsadh A; Fang Z; Braidy N; Voineagu I
    Genom Data; 2017 Mar; 11():113-115. PubMed ID: 28119819
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics, Pharmacodynamics, and Side Effects of Midazolam: A Review and Case Example.
    Peter JU; Dieudonné P; Zolk O
    Pharmaceuticals (Basel); 2024 Apr; 17(4):. PubMed ID: 38675433
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Role of CYP3A in Health and Disease.
    Klyushova LS; Perepechaeva ML; Grishanova AY
    Biomedicines; 2022 Oct; 10(11):. PubMed ID: 36359206
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Central Role of Cytochrome P450 in Xenobiotic Metabolism-A Brief Review on a Fascinating Enzyme Family.
    Esteves F; Rueff J; Kranendonk M
    J Xenobiot; 2021 Jun; 11(3):94-114. PubMed ID: 34206277
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Changes and sex- and age-related differences in the expression of drug metabolizing enzymes in a KRAS-mutant mouse model of lung cancer.
    Li X; Lu Y; Ou X; Zeng S; Wang Y; Qi X; Zhu L; Liu Z
    PeerJ; 2020; 8():e10182. PubMed ID: 33240601
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Network-based analysis of transcriptional profiles from chemical perturbations experiments.
    Mulas F; Li A; Sherr DH; Monti S
    BMC Bioinformatics; 2017 Mar; 18(Suppl 5):130. PubMed ID: 28361664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.